Short summary: A new systematic review looked at GLP-1 receptor agonist medicines in children and teens with obesity or youth-onset type 2 diabetes. The review found benefits in selected studies, including lower body mass index in adolescents with obesity and improved HbA1c in youth-onset type 2 diabetes. The authors also stressed that longer-term safety data are still needed.
What happened
Researchers published a systematic review in Diabetes Research and Clinical Practice on GLP-1 receptor agonists in children and adolescents with obesity or type 2 diabetes.
The review included PubMed-indexed studies published from 2000 to 2025. It summarized seven pivotal randomized controlled trials and six meta-analyses involving 901 participants aged 6 to under 18 years.
Why this matters
Families are hearing more about GLP-1 medicines because they are widely discussed for weight and type 2 diabetes in adults. Pediatric care is different. Children and teenagers are still growing, and treatment decisions need specialist supervision, careful monitoring, and realistic expectations.
This review is useful because it brings together the current pediatric evidence while also naming the unanswered safety questions.
What the review found
For adolescents with obesity, the review reported that semaglutide 2.4 mg once weekly produced the greatest body mass index reduction among the medicines reviewed. Liraglutide 3.0 mg daily improved body mass index standard deviation score in adolescents and younger children. These were study doses reported in the review, not dosing instructions. Approved use and dosing can vary by age, diagnosis, country, and product label.
For youth-onset type 2 diabetes, liraglutide 1.8 mg daily and dulaglutide significantly improved HbA1c compared with placebo in the studies reviewed.
The review also reported improvements in insulin resistance and modest triglyceride reductions with weight-reducing agents. Changes in LDL cholesterol were minimal.
Safety and side effects
The most common side effects were gastrointestinal, mainly nausea and vomiting. The review described these side effects as generally transient and dose dependent.
The review did not find significant adverse effects on linear growth or pubertal progression in the available studies. In this LivingDiabetes summary, we treat that as reassuring but incomplete because available studies do not prove long-term safety for every child.
The authors called for longer-term studies to assess cardiovascular safety, bone health, and growth outcomes.
What this does not mean
This review does not mean GLP-1 medicines are right for every child with obesity or type 2 diabetes. It does not recommend any specific medicine or dose for an individual child.
These medicines should not be started, stopped, or changed without guidance from a qualified healthcare professional. Families should discuss benefits, side effects, monitoring, cost, availability, and long-term uncertainties with a pediatric diabetes, endocrinology, or obesity-care team.
Practical takeaway
If your child or teenager is living with obesity or type 2 diabetes, this review can help you ask better questions. Ask what treatment options are appropriate, what benefits are realistic, what side effects to watch for, and how growth, puberty, mental health, nutrition, activity, sleep, and family support will be monitored over time.
Medication is only one part of pediatric care. Nutrition, physical activity, sleep, emotional wellbeing, family routines, and regular follow-up remain important whether or not medicine is used.
Evidence and source summary
- Study type: Systematic review of pediatric GLP-1 receptor agonist evidence.
- Evidence base: The review summarized seven pivotal randomized controlled trials and six meta-analyses. The PubMed abstract reports 901 participants aged 6 to under 18 years.
- Main source: PubMed record PMID 42365860.
- DOI: 10.1016/j.diabres.2026.113400.
- Key limitation: Longer-term evidence is still needed for cardiovascular safety, bone health, and growth outcomes.
OpenAI correction and safety check notes
This draft was checked for medical accuracy, unsupported claims, drug names, pediatric safety caveats, tone, and patient-safety framing. The final wording avoids recommending any specific drug or dose and emphasizes specialist-led decisions.
OpenRouter and Perplexity verification notes
OpenRouter with a Perplexity model was used to verify the main claims against the cited PubMed source. The verification supported the study type, participant age range, medicine classes, reported benefits, gastrointestinal side-effect caveat, and need for longer-term safety data.
Suggested categories and tags
Categories: News, Type 2 diabetes, Diabetes Medication, Weight Loss.
Tags: GLP-1, pediatric diabetes, childhood obesity, type 2 diabetes in children, semaglutide, liraglutide, dulaglutide.